Go Pro
→ Elon Is Quietly Doubling Down on This Bizarre Asset (From Brownstone Research) (Ad)tc pixel Free DXR Stock Alerts

Daxor (DXR) Competitors

Daxor logo
$10.66 +0.56 (+5.49%)
As of 10:36 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

DXR vs. OBIO, TLSI, SMTI, RXST, and KRMD

Should you buy Daxor stock or one of its competitors? MarketBeat compares Daxor with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Daxor include Orchestra BioMed (OBIO), TriSalus Life Sciences (TLSI), Sanara MedTech (SMTI), RxSight (RXST), and KORU Medical Systems (KRMD). These companies are all part of the "medical equipment" industry.

How does Daxor compare to Orchestra BioMed?

Daxor (NASDAQ:DXR) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

1.3% of Daxor shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 51.5% of Daxor shares are owned by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Daxor has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Orchestra BioMed has a consensus target price of $13.60, indicating a potential upside of 267.57%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Orchestra BioMed
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

In the previous week, Orchestra BioMed had 1 more articles in the media than Daxor. MarketBeat recorded 3 mentions for Orchestra BioMed and 2 mentions for Daxor. Daxor's average media sentiment score of 0.96 beat Orchestra BioMed's score of 0.30 indicating that Daxor is being referred to more favorably in the media.

Company Overall Sentiment
Daxor Positive
Orchestra BioMed Neutral

Daxor has higher earnings, but lower revenue than Orchestra BioMed.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaxorN/AN/AN/AN/AN/A
Orchestra BioMed$33.48M6.62-$52.70M-$0.97N/A

Daxor has a net margin of 0.00% compared to Orchestra BioMed's net margin of -166.96%. Daxor's return on equity of 0.00% beat Orchestra BioMed's return on equity.

Company Net Margins Return on Equity Return on Assets
DaxorN/A N/A N/A
Orchestra BioMed -166.96%-157.46%-60.18%

Summary

Orchestra BioMed beats Daxor on 7 of the 12 factors compared between the two stocks.

How does Daxor compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Daxor had 1 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 2 mentions for Daxor and 1 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 1.89 beat Daxor's score of 0.96 indicating that TriSalus Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
TriSalus Life Sciences Very Positive
Daxor Positive

TriSalus Life Sciences has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Daxor has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

TriSalus Life Sciences currently has a consensus target price of $7.50, indicating a potential upside of 76.68%. Given TriSalus Life Sciences' higher probable upside, equities research analysts clearly believe TriSalus Life Sciences is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TriSalus Life Sciences
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Daxor has lower revenue, but higher earnings than TriSalus Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TriSalus Life Sciences$45.15M5.77-$39.23M-$1.41N/A
DaxorN/AN/AN/AN/AN/A

Daxor has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -60.85%.

Company Net Margins Return on Equity Return on Assets
TriSalus Life Sciences-60.85% N/A -69.91%
Daxor N/A N/A N/A

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by insiders. Comparatively, 51.5% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

TriSalus Life Sciences beats Daxor on 6 of the 11 factors compared between the two stocks.

How does Daxor compare to Sanara MedTech?

Daxor (NASDAQ:DXR) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, Daxor and Daxor both had 2 articles in the media. Sanara MedTech's average media sentiment score of 1.45 beat Daxor's score of 0.96 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company Overall Sentiment
Daxor Positive
Sanara MedTech Positive

Daxor has higher earnings, but lower revenue than Sanara MedTech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaxorN/AN/AN/AN/AN/A
Sanara MedTech$103.12M2.11-$37.56M-$3.77N/A

Daxor has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

1.3% of Daxor shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 51.5% of Daxor shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Daxor has a net margin of 0.00% compared to Sanara MedTech's net margin of -31.23%. Daxor's return on equity of 0.00% beat Sanara MedTech's return on equity.

Company Net Margins Return on Equity Return on Assets
DaxorN/A N/A N/A
Sanara MedTech -31.23%-3.19%-0.56%

Sanara MedTech has a consensus target price of $34.00, suggesting a potential upside of 43.25%. Given Sanara MedTech's stronger consensus rating and higher possible upside, analysts clearly believe Sanara MedTech is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Sanara MedTech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60

Summary

Sanara MedTech beats Daxor on 8 of the 12 factors compared between the two stocks.

How does Daxor compare to RxSight?

RxSight (NASDAQ:RXST) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

RxSight currently has a consensus price target of $8.89, indicating a potential upside of 79.46%. Given RxSight's higher probable upside, equities research analysts clearly believe RxSight is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RxSight
3 Sell rating(s)
7 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.92
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

RxSight has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Daxor has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

In the previous week, RxSight had 8 more articles in the media than Daxor. MarketBeat recorded 10 mentions for RxSight and 2 mentions for Daxor. Daxor's average media sentiment score of 0.96 beat RxSight's score of 0.30 indicating that Daxor is being referred to more favorably in the news media.

Company Overall Sentiment
RxSight Neutral
Daxor Positive

78.8% of RxSight shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 10.1% of RxSight shares are owned by company insiders. Comparatively, 51.5% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Daxor has a net margin of 0.00% compared to RxSight's net margin of -36.58%. Daxor's return on equity of 0.00% beat RxSight's return on equity.

Company Net Margins Return on Equity Return on Assets
RxSight-36.58% -17.01% -15.12%
Daxor N/A N/A N/A

Daxor has lower revenue, but higher earnings than RxSight.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RxSight$134.48M1.52-$38.94M-$1.13N/A
DaxorN/AN/AN/AN/AN/A

Summary

RxSight and Daxor tied by winning 6 of the 12 factors compared between the two stocks.

How does Daxor compare to KORU Medical Systems?

KORU Medical Systems (NASDAQ:KRMD) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Daxor has lower revenue, but higher earnings than KORU Medical Systems.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KORU Medical Systems$41.13M4.62-$2.64M-$0.05N/A
DaxorN/AN/AN/AN/AN/A

In the previous week, KORU Medical Systems had 1 more articles in the media than Daxor. MarketBeat recorded 3 mentions for KORU Medical Systems and 2 mentions for Daxor. Daxor's average media sentiment score of 0.96 beat KORU Medical Systems' score of 0.62 indicating that Daxor is being referred to more favorably in the news media.

Company Overall Sentiment
KORU Medical Systems Positive
Daxor Positive

58.6% of KORU Medical Systems shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 18.5% of KORU Medical Systems shares are held by insiders. Comparatively, 51.5% of Daxor shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Daxor has a net margin of 0.00% compared to KORU Medical Systems' net margin of -5.27%. Daxor's return on equity of 0.00% beat KORU Medical Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
KORU Medical Systems-5.27% -13.61% -8.33%
Daxor N/A N/A N/A

KORU Medical Systems presently has a consensus target price of $7.25, indicating a potential upside of 75.29%. Given KORU Medical Systems' stronger consensus rating and higher possible upside, equities research analysts clearly believe KORU Medical Systems is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KORU Medical Systems
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

KORU Medical Systems has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Daxor has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

Summary

KORU Medical Systems beats Daxor on 7 of the 12 factors compared between the two stocks.

Get Daxor News Delivered to You Automatically

Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DXR vs. The Competition

Export
MetricDaxorMED IndustryMedical SectorNASDAQ Exchange
Market Cap$62.28M$6.22B$6.74B$12.51B
Dividend YieldN/A1.41%2.68%8.00%
P/E RatioN/A40.7026.9024.39
Price / SalesN/A30.24587.69117.46
Price / CashN/A19.2129.2249.36
Price / BookN/A3.7010.926.33
Net IncomeN/A$218.81M$3.58B$330.66M
7 Day Performance1.77%-0.44%-2.25%-0.84%
1 Month Performance7.25%13.30%3.08%-0.26%
1 Year Performance14.31%34.67%26.23%19.99%

Daxor Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXR
Daxor
1.9238 of 5 stars		$10.67
+5.5%		N/A+12.1%$62.28MN/AN/A37
OBIO
Orchestra BioMed
4.2243 of 5 stars		$3.92
flat		$13.60
+246.9%		+30.8%$234.73M$33.48MN/A4
TLSI
TriSalus Life Sciences
3.0325 of 5 stars		$3.89
+5.7%		$7.50
+92.8%		-13.5%$226.01M$45.15MN/A106
SMTI
Sanara MedTech
2.4429 of 5 stars		$23.88
-1.4%		$34.00
+42.4%		-14.2%$222.04M$103.12MN/A60
RXST
RxSight
2.8648 of 5 stars		$5.08
-4.9%		$8.89
+75.0%		-36.8%$221.06M$134.48MN/A220

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DXR) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
American’s Biggest Threat Is Here
This feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...
Goldco Direct, LLC | Sponsoredtc pixel
They proved it worked in '76. Then buried it.
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
This Is How Financial Freedom Dies—And Most People Never See It Coming
While the trade war grabs headlines, the Department of Justice has quietly argued in court that cash may not b...
Priority Gold | Sponsoredtc pixel